Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.American journal of respiratory cell and molecular biology · 2018
   Review
2. New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.European respiratory review : an official journal of the European Respiratory Society · 2017
   Review
3. Cutaneous Manifestations of Sarcoidosis Seen in a Patient with a History of Tuberous Sclerosis.Case reports in dermatology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as